Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Pramlintide (Primary)
- Indications Hypoglycaemia
- Focus Proof of concept; Therapeutic Use
- 25 Apr 2017 Planned End Date changed from 1 May 2015 to 1 Oct 2018.
- 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 14 May 2015 New trial record